Soligenix, Inc. reports developments as a late-stage biopharmaceutical company focused on rare diseases and public health medical countermeasures. Company news centers on HyBryte (synthetic hypericin), a visible-light activated therapy program for cutaneous T-cell lymphoma, and SGX945 (dusquetide) for Behçet's Disease, including clinical data, published study results and regulatory designations.
Updates also cover the Public Health Solutions segment, including RiVax ricin toxin vaccine candidate, filovirus vaccine programs, CiVax for COVID-19 and the ThermoVax heat-stabilization platform. Recurring announcements include operating and financial results, government-supported development activities, material agreements, shareholder voting matters and governance updates.
Soligenix announced positive results from its HyBryte™ compatibility study for treating cutaneous T-cell lymphoma (CTCL), published in JEADV Clinical Practice. The study, HPN-CTCL-02, enrolled 9 patients, revealing a 22% treatment response rate after 8 weeks of HyBryte™ therapy. The results align with the Phase 3 FLASH trial, showing an average improvement of 36.4% in cumulative mCAILS scores. Key metrics included low systemic hypericin levels and no adverse effects on cardiac rhythm, confirming HyBryte™'s safety. The study points to the potential real-world use of HyBryte™ and precedes a confirmatory Phase 3 FLASH2 study.
Soligenix, a biopharmaceutical company, announced recent accomplishments and first quarter 2024 financial results. They completed a public offering with gross proceeds of $4.75 million, received orphan drug designations, and initiated various clinical trials. The company's revenue decreased to $0.1 million, net loss increased to $1.9 million, research and development expenses grew due to upcoming trials, and general and administrative expenses decreased. Cash position was $7.1 million as of March 31, 2024.
Soligenix, Inc. (Nasdaq: SNGX) announced its participation in upcoming conferences like the Aegis Virtual Conference, BioNJ's 14th Annual BioPartnering Conference, and A.G.P./Alliance Global Partners Healthcare Company Showcase. These events provide opportunities for presentations, networking, and one-on-one meetings with key members of Soligenix management. The Company aims to deliver a corporate presentation to investors, institutional funds, and money managers, showcasing its late-stage biopharmaceutical products for rare diseases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.